Becton Dickinson said worldwide revenues in 2025 were $21.840 billion, an increase of 8.2% from the prior-year period. The company said this increase reflected the impact of foreign currency and the acquisition of Advanced Patient Monitoring.

1. 01

   Becton Dickinson said worldwide revenues in 2025 were $21.840 billion, an increase of 8.2% from the prior-year period. The company said this increase reflected the impact of foreign currency and the acquisition of Advanced Patient Monitoring.

2. 02

   Becton Dickinson said cash flows from continuing operating activities in 2025 were $3.430 billion and cash and equivalents and short-term investments, including restricted cash, were $859 million. The company paid cash dividends to common shareholders of $1.196 billion in the same year and repurchased approximately $1 billion of common stock.

3. 03

   Becton Dickinson said it entered into a definitive agreement on July 13, 2025 to combine its Biosciences and Diagnostic Solutions business with Waters. The company also said it reorganized its organizational units into 5 segments—Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences—effective October 1, 2025.

4. 04

   Becton Dickinson said in Q4 of fiscal 2025 it refinanced its existing revolving credit facility that was scheduled to mature in September 2025 with a new senior unsecured revolving credit facility maturing in September 2030 with a maximum commitment of $2.750 billion. As of September 30, 2025, the company had no borrowings outstanding under the revolving credit facility and commercial paper borrowings of $855 million.

Key figures

Fiscal year ended September 30, 2025

Revenue

$21.8B

Operating income

$2.6B

Net income

$1.7B

EPS

$5.82

Operating cash flow

$3.4B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.